# Tirzepatide References: Full Citation List with DOIs and PubMed Links

> Complete Tirzepatide references list: 13 peer-reviewed sources including SURPASS-2, SURMOUNT-1, SURMOUNT-5, the Sattar MACE meta-analysis, SUMMIT HFpEF, and the lipid-profile meta-analysis.

Peer-reviewed publications, with DOIs and PubMed URLs.

## Peer-reviewed sources

[Tirzepatide references](/references) — see the full indexed list below. Every quantitative claim on this site is cited to one of these sources.

## References

[1] Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. https://pubmed.ncbi.nlm.nih.gov/34170647/
[2] Sattar N, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591-598. https://pubmed.ncbi.nlm.nih.gov/35210595/
[3] Mahar MU, et al. The Effects of Tirzepatide on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Obes Metab Syndr. 2024. https://pubmed.ncbi.nlm.nih.gov/39681390/
[4] Zeng Q, et al. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023. https://pubmed.ncbi.nlm.nih.gov/37908750/
[5] Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. https://pubmed.ncbi.nlm.nih.gov/30473097/
[6] Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
[7] Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. https://pubmed.ncbi.nlm.nih.gov/32730231/
[8] Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40353578/
[9] Farzam K, Patel P. Tirzepatide. StatPearls [Internet], NCBI Bookshelf. 2024. https://www.ncbi.nlm.nih.gov/books/NBK585056/
[10] Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT). N Engl J Med. 2025. https://pubmed.ncbi.nlm.nih.gov/41406444/
[11] Dahl D, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-5). Lancet. 2021. https://pubmed.ncbi.nlm.nih.gov/34672967/
[12] Thomas MK, et al. Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1). J Endocr Soc. 2023;7(6):bvad056. https://pubmed.ncbi.nlm.nih.gov/37153701/
[13] Wharton S, et al. Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS trials. Diabetes Obes Metab. 2024. https://pubmed.ncbi.nlm.nih.gov/37853960/

---

Trial figures, mechanism notes, and safety signals — tabulated from the published literature, with no clinical role held.